Cyclerion Therapeutics
CYCN
37 hedge funds and large institutions have $18.3M invested in Cyclerion Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 6 closing their positions.
59% more capital invested
Capital invested by funds: $11.5M → $18.3M (+$6.79M)
0.04% more ownership
Funds ownership: 2.41% → 2.44% (+0.04%)
10% less funds holding
Funds holding: 41 → 37 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$753K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.16K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.7K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$791 |
| 5 |
GAG
Goodman Advisory Group
Needham,
Massachusetts
|
+$309 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$148K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$88.9K |
| 3 |
Two Sigma Advisers
New York
|
-$51.6K |
| 4 |
Jane Street
New York
|
-$32K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$29.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| $9K | +$9.16K | +533 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $8K | -$3.88K | -226 | -33% |
|
28
Morgan Stanley
New York
| $3K | -$1.6K | -93 | -35% |
|
29
BNP Paribas Financial Markets
Paris,
France
| $273 | – | – | – |
|
|
30
Jane Street
New York
| – | -$32K | -2,915 | Closed |
|
31
Prudential Financial
Newark,
New Jersey
| – | -$29K | -2,614 | Closed |
|
|
DC
32
Davenport & Co
Richmond,
Virginia
| – | -$7K | -650 | Closed |
|
33
Simplex Trading
Chicago,
Illinois
| – | -$2.32K | -135 | -79% |
|
|
HNWAG
34
High Net Worth Advisory Group
Naples,
Florida
| – | -$1K | -50 | Closed |
|
35
Wells Fargo
San Francisco,
California
| – | -$34 | -2 | -10% |
|
36
Bank of America
Charlotte,
North Carolina
| – | -$17 | -1 | Closed |
|
|
GAG
37
Goodman Advisory Group
Needham,
Massachusetts
| – | +$309 | +18 | New |
|
CYCN Hedge Fund Activity: Q3 2022 in Review
37 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2022, worth a combined $18.3M — up 59% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CYCN and 2 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 4 added.
The largest buyer was Fidelity Investments, adding an estimated $753K. The largest seller was Renaissance Technologies, cutting an estimated $148K.
- 37 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2022, down from 41 in Q2 2022.
- Funds reported $18.3M of Cyclerion Therapeutics stock for Q3 2022, up 59% quarter-over-quarter.
- 2 funds opened new Cyclerion Therapeutics positions in Q3 2022 and 6 closed out, a net change of -4 holders.
- The largest Cyclerion Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $753K added.
- The largest Cyclerion Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $148K sold.
Based on aggregated 13F filings for Q3 2022.